Glenmark Pharmaceuticals Ltd. is a research-driven, global, integrated pharmaceutical company.
Glenmark is a leading player in the discovery of new molecules, both NCEs (new chemical entity) and NBEs (new biological entity), with seven molecules in various stages of clinical development pre-clinical development.
The company has a significant presence in branded generics markets across emerging economies including India. It’s subsidiary, Glenmark Generics Limited has a fast growing and robust US generics business. The subsidiary also markets APIs to regulated and semi-regulated countries. Glenmark employs over 10,400 people in over 80 countries. It has 14 manufacturing facilities in four countries and has 6 R D centres.
Since getting listed on the stock exchange in 2000, when Glenmark registered revenue of USD 32 Mn, the company is currently ranked among the World’s top 100 Pharma Biotech companies*. Recently, Glenmark has been chosen as the ‘Best Company Across Emerging Markets’ 2011 and recognised for the ‘Best Overall Pipeline’ 2011 by SCRIP, the largest selling and most respected pharmaceutical magazine in the world. SCRIP had also identified Glenmark as ‘Best Pharma Company in the World – SME’ and ‘Best Company in an Emerging Market’ in 2008.
Other awards and recognition received by the firm include the “Best under a Billion Dollar companies in Asia” for 2008 by Forbes; a leading international publication, “Indian Innovator Pharmaceutical Company of the Year – 2010” by Frost Sullivan; and Gold Patent Award 2011 in the categories of API Formulations Export of bulk drugs (Non Biologicals) by Pharmexcil.